AustralianSuper’s Vertex Pharmaceuticals VRTX Stock Holding History

AustralianSuper’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Hold	3,032	–	–	0.01%	248
2026 Q1	$1.35M	Hold	3,032	–	–	0.01%	252
2025 Q4	$1.37M	Hold	3,032	–	–	0.01%	246
2025 Q3	$1.19M	Sell	3,032 -48,224	-94%	-$20.2M	0.01%	247
2025 Q2	$22.8M	Sell	51,256 -76,687	-60%	-$35.3M	0.12%	141
2025 Q1	$62M	Sell	127,943 -91,132	-42%	-$42.5M	0.35%	81
2024 Q4	$88.2M	Sell	219,075 -7,299	-3%	-$3.38M	0.42%	72
2024 Q3	$105M	Buy	+226,374	New	+$109M	0.52%	56
2024 Q2	–	Sell	-11,441	Closed	-$4.81M	–	266
2024 Q1	$4.81M	Buy	11,441 +1,095	+11%	+$463K	0.03%	153
2023 Q4	$4.21M	Buy	+10,346	New	+$3.82M	0.03%	176

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AustralianSuper's VRTX Position: Q2 2026 in Review

AustralianSuper held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 3,032 shares worth $1.51M. The position accounts for 0.01% of the portfolio, ranked #248.

AustralianSuper first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $105M in Q3 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

AustralianSuper held 3,032 shares of Vertex Pharmaceuticals worth $1.51M as of Q2 2026.
AustralianSuper left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of AustralianSuper's portfolio in Q2 2026, its #248 holding.
AustralianSuper first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
AustralianSuper's Vertex Pharmaceuticals position peaked at $105M in Q3 2024.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.